Myriad to Present New Data for Its Expanded Carrier and Noninvasive Prenatal Screens at the 2019 Society for Maternal-Fetal M...
February 08 2019 - 7:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular
diagnostics and personalized medicine, today announced that its
Myriad Women’s Health business unit will present new data from
eight studies at the 2019 Society for Maternal-Fetal Medicine
(SMFM) being held Feb. 11-16, 2019 in Las Vegas, NV.“We look
forward to presenting important data from our comprehensive women’s
health portfolio, including our Foresight® Carrier Screen and
Prequel Prenatal Screen™,” said James Goldberg, M.D., board
certified maternal fetal medicine specialist, medical geneticist
and chief medical officer, Myriad Women’s Health. “We are
particularly excited to be sharing data that demonstrates the
clinical validity of our Prequel test below a fetal fraction of
four percent, which means more patients receive reliable results
the first time. We believe the high accuracy of Prequel at
any fetal fraction level is a key differentiator to other
noninvasive prenatal screening tests on the market.”
Please visit Myriad Women’s Health at booth 401 to learn more
about our leading portfolio of women’s health products.
Follow Myriad on Twitter via @myriadgenetics and keep up to date
with meeting news and updates by using the hashtag #SMFM19.
|
|
Featured Research at 2019 SMFM |
Product |
Abstract |
Poster Details(Saturday, Feb. 16) |
Foresight®CarrierScreen |
Detection of Copy-Number Variants in Expanded CarrierScreening
Maximizes Identification of Cystic Fibrosis Carriers. |
Poster: 866 |
A Data-Driven Approach for Determining Optimal Content forExpanded
Carrier Screening Panels. |
Poster: 916 |
Clinical Utility of Expanded Carrier Screening:
Results-GuidedActionability and Outcomes. |
Poster: 893 |
Education and genetic counseling in the era of expandinggenetic
technology. |
Poster: 876 |
|
Prequel™PrenatalScreen |
Clarity from discordance: Leveraging fetal fraction reducesfalse
positives in noninvasive prenatal screening. |
Poster: 915 |
Avoiding unnecessary trade-offs: Clinical experience for
anoninvasive prenatal screen with both low no-call rate andhigh
accuracy. |
Poster: 923 |
Leveraging whole genome sequencing in noninvasive
prenatalscreening: a case of Prader Willi syndrome due to
uniparentaldisomy. |
Poster: 922 |
Rare Adds Up: Characterization of Mosaicism in RareAutosomal
Aneuploidies via Noninvasive Prenatal Screening |
Poster: 877 |
About Foresight® Carrier
ScreenThe Myriad Foresight Carrier Screen is designed to
maximize detection of at-risk couples for serious, prevalent, and
clinically-actionable conditions. Foresight has a rigorous disease
selection that focuses on 175+ conditions that provides meaningful
information to patients. Additionally, Foresight offers superior
technology with unmatched detection rates for the vast majority of
genes on the panel (>99% across ethnicities) which means
patients can trust both positive and negative results.
About Prequel™ Prenatal
ScreenThe Myriad Prequel Prenatal Screen is a noninvasive
prenatal screen that uses cell-free DNA (cfDNA) to determine if a
pregnancy is at an increased risk for common chromosome
abnormalities, such as Down syndrome. Prequel has been shown
to be superior to screening methods that use maternal age,
ultrasound and serum screening. Additionally, Prequel has a
lower false-positive rate and false-negative rate than these other
methods. The Prequel Prenatal Screen can be ordered with the
Foresight Carrier Screen and offered to all women, including those
with high body mass index, and ovum donor or a twin
pregnancy.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five strategic imperatives: build upon a solid hereditary
cancer foundation, growing new product volume, expanding
reimbursement coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP,
myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice,
myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD,
EndoPredict, Vectra, GeneSight, riskScore Prolaris, Foresight and
Prequel are trademarks or registered trademarks of Myriad Genetics,
Inc. or its wholly owned subsidiaries in the United States and
foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements related to the Company’s presentation of new data for
its expanded carrier and noninvasive prenatal screens being
featured at the Society of Maternal-Fetal Medicine Feb. 11-16, 2019
in Las Vegas, NV; the ability of the Prequel test to demonstrate
the extremely high accuracy below a fetal fraction of four percent;
the ability of the Prequel test to provide patients reliable
results the first time; the Company’s belief that the high accuracy
of the Prequel test at any fetal fraction is a key differentiator
to other noninvasive prenatal screening tests on the market; and
the Company's strategic directives under the caption "About Myriad
Genetics." These "forward-looking statements" are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that sales
and profit margins of our molecular diagnostic tests and
pharmaceutical and clinical services may decline; risks related to
our ability to transition from our existing product portfolio to
our new tests, including unexpected costs and delays; risks related
to decisions or changes in governmental or private insurers’
reimbursement levels for our tests or our ability to obtain
reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services and any future tests and services are terminated or cannot
be maintained on satisfactory terms; risks related to delays or
other problems with operating our laboratory testing facilities and
our healthcare clinic; risks related to public concern over genetic
testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; the risk that
we may be unable to comply with financial operating covenants under
our credit or lending agreements; the risk that we will be
unable to pay, when due, amounts due under our credit or lending
agreements; and other factors discussed under the heading "Risk
Factors" contained in Item 1A of our most recent Annual Report on
Form 10-K for the fiscal year ended June 30, 2018, which has been
filed with the Securities and Exchange Commission, as well as any
updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. All information in this press release is as of the date
of the release, and Myriad undertakes no duty to update this
information unless required by law.
|
Media
Contact: |
Ron Rogers |
Investor
Contact: |
Scott Gleason |
|
(801) 584-3065 |
|
(801) 584-1143 |
|
rrogers@myriad.com |
|
sgleason@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024